---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-036981"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2023-10-12T23:59:59+00:00"
generated_at: "2026-06-10T00:38:34.114528+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CMS expands carotid stenting coverage to asymptomatic/standard-risk patients; InspireMD supports

## Summary
- CMS final NCD extends CAS coverage to asymptomatic and standard-risk patients, expanding addressable market.
- InspireMD advancing CAS and TCAR programs in U.S. and E.U. using CGuard EPS stent system.
- C-GUARDIANS IDE trial completed enrollment; 30-day safety results at VIVA Nov 1, 2023; PMA filing anticipated H2 2024.
- CGuard EPS stent studied in nine clinical trials with >1,850 patients and over 40,000 real-world procedures.
- CEO says CMS decision will accelerate shift from open surgery to endovascular 'stent first' approach.

## SEC filing metadata
- accession: 0001493152-23-036981
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2023-10-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315223036981/0001493152-23-036981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315223036981/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-036981
- JSON: https://secwatch.observer/filing/0001493152-23-036981.json
- Plain text: https://secwatch.observer/filing/0001493152-23-036981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.